"Also he made a pretty positive statement here,.. if true then it could explain what the company is sharing with HL and others to continually get financing. The eGFR is low in ALL patients, both Treated and Placebo groups,.. so it would be an amazing indicator if eGFR was up,... it could ONLY mean it comes from the treated group."

I agree that if Resverlogix is privy to the blinded clinical measurements (i.e., eGFR, MoCA, alkaline phosphatase, HDL-C, apo-AI, fasting glucose, HbA1c), that postive and enouraging trends of improvement could potentially be seen. For many of these clinical measurements, one expects them to not change or worsen in the placebo group, but improve in the apabetalone group. So a change in the positive direcition for the blinded data of all patients could be interpreted as being due to a strong apabetalone benefit. However, there are other interpretations such as both apabetalone and placebo group improving indepedent of apabetalone effect. Phase 2 data would argue against this possibility, but one must still consider it as a possibility in BETonMACE.

BearDownAZ